Table 2.
Cost-Utility of Lateral-Flow Urine LAM Detection
| Country and Diagnostic Strategy | Cohort Sizea | TB Cases | TB Cases Treated | False-Positives Treated | DALYs | DALYs averted | Cost (2010 US$) | Incremental Cost | Incremental Cost-Effectiveness ($/DALY) |
|---|---|---|---|---|---|---|---|---|---|
| South Africa | |||||||||
| Existing Diagnostics | 1000 | 380 | 262 | 130 | 1491 | (ref) | $299,000 | (ref) | (ref) |
| Existing Diagnostics + Urine LAM | 1000 | 380 | 342 | 155 | 1267 | 224 | $378,000 | $79,000 | $353 |
| Uganda | |||||||||
| Existing Diagnostics | 1000 | 380 | 262 | 130 | 1491 | (ref) | $64,000 | (ref) | (ref) |
| Existing Diagnostics + Urine LAM | 1000 | 380 | 342 | 155 | 1267 | 224 | $83,000 | $19,000 | $208 |
DALY, disability-adjusted life year; LAM, lipoarabinomannan; TB, tuberculosis